Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-17 of 17 for your search:
Cancer Type/Condition:
childhood atypical teratoid/rhabdoid tumor
Stage/Subtype:
childhood atypical teratoid/rhabdoid tumor
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 10 at diagnosis
Sponsor:
Other
Protocol IDs:
CHLA-HEAD-START-III
, CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
2.
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and under at the time of definitive surgery
Sponsor:
NCI
Protocol IDs:
COG-ACNS0333
, ACNS0333, NCT00653068
3.
Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
3 to 21 at diagnosis
Sponsor:
NCI, Other
Protocol IDs:
CDR0000367486
, SJCRH-SJMB03, NCT00085202
4.
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-110
, SUN08-01, NCT00704054
5.
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
6.
PF-02341066 in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
COG-ADVL0912
, ADVL0912, NCT00939770
7.
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 30
Sponsor:
Other
Protocol IDs:
OHSU-5056
, OHSU SOL-08131-L, NCT00983398
8.
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
MSKCC-05122
, NCT00445965
9.
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 21 years
Sponsor:
Other
Protocol IDs:
NYU 05-40 H12853
, PBMTC ONC-032P, NCT00528437
10.
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
MSKCC-03133
, NCT00089245
11.
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-020
, NCT00326664
12.
Trabectedin in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
4 to 16
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0054
, NCT00437047
13.
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
3 to 21
Sponsor:
NCI
Protocol IDs:
PBTC-024
, PBTC-024, NCI-09-C-0112, NCT00572182
14.
Bone Marrow Radiation Therapy Followed by Busulfan, Melphalan, Thiotepa, and an Autologous Stem Cell Transplant in Treating Patients With High-Risk or Relapsed Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
70 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS023
, UMN-2005LS023, UMN-MT2004-30, NCT00623077
15.
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 months to 23 years
Sponsor:
Other
Protocol IDs:
ACH-CNS-001
, NCT00876993
16.
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
PBTC-027
, PBTC-027, NCT00946335
17.
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Central Nervous System Tumors
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 3 at diagnosis
Sponsor:
Other
Protocol IDs:
CDR0000580360
, SJCRH-SJYC07, NCT00602667
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
